Ocular Diseases Forum 2 was held in Washington, DC on Saturday, September 28, 2024

Materials

Agenda

Meeting Summary

Participant List

Session I: Introductions & Project Overview

 Welcome & Introductions
Veronica Miller, Forum
José-Alain Sahel, UPMC*
Jim Wang, Regeneron

Governance & Forum Process
Sehyr Khan, Forum
Alessi Ayvaz, Forum

Objectives for Ocular Diseases Forum 2 (ODF2)
Claire M. Gelfman, Forum
Jim Wang, Regeneron

Regulatory Perspective: Call for Collaboration
Heidi Becker & Lola Fashoyin-Aje, Center for Biologics Evaluation and Research, FDA

Session II: Endpoints for IRDs: Building Consensus

Landscape for IRD Drug Development: Potential Endpoints in Clinical Trials
Tomas Aleman, Scheie Eye Institute, University of Pennsylvania

Regulatory Endpoints and Trial Design for IRDs [REDI] Working Group – RUSH2A Key Findings
Jacque Duncan, UCSF Department of Ophthalmology*

FFB Clinical Consortium FST Data Review
David Birch, Retina Foundation of the Southwest

FST in Clinical Trials: Phase I/II Data
Laura Pardon, Atsena Therapeutics

Session II: Endpoints for IRDs: Building Consensus (Continued)

Questionably/Definitely/Decreased AutoFluorescence (QDAF, DDAF, DAF) on Short Wavelength-AutoFluorescence: Current Understanding and Rationale
Bart Leroy, Ghent University

Session III: Patient Perspectives in IRDs and AMD: Call for Clinical Trials and a Path Forward

Living with Retinal Disease: A Patient (Parent) Perspective
Marylee Dilling, Blue Cone Monochromacy Families Foundation

Patient Engagement Strategies in Clinical Trials
Julia Carpenter-Conlin, Alkeus

Session IV: PROs and PROMs

Current Landscape for AMD Drug Development
Cheryl Rowe-Rendleman, Omar Consultants*

Case Study: GA Clinical Trials
Peter Kaiser, Cole Eye Institute*

Session V: Wrap Up & Next Steps

Summary & Next Steps
Veronica Miller, Forum